{
  "url": "https://www.law.cornell.edu/regulations/new-york/9-NYCRR-9960.3",
  "title": "N.Y. Comp. Codes R. & Regs. Tit. 9 ยง 9960.3 - Procedures for determinations relating to package, dosage form or form of administration",
  "content": "N.Y. Comp. Codes R. & Regs. Tit. 9 ยง 9960.3 - Procedures for determinations relating to package, dosage form or form of administration\n\nState Regulations\n\nFor purposes of designating a given package, dosage form or\nform of administration as excluded from coverage, the following shall\napply: (a) An initial determination\nbased upon information and facts available, shall be made by the department\nutilizing such considerations as: (1)\nthe\navailability of low-cost alternative packaging, dosage form or forms of\nadministration; (2)\nany particular\nhealth needs of the EPIC population; (3)\nthe degree to which the packaging, dosage\nform or form of administration offers comfort, convenience or ease of\nadministration at added cost; (4)\navailability of pharmaceutically equivalent and therapeutically equivalent\nproducts for the covered population; (5)\nany drug marketed as a therapeutic agent\nwith official labeling which states that the product is contraindicated by\nvirtue of age or therapeutic condition for program participants; or\n(6)\nrecommendations of the Technical Pharmacy\n\nAdvisory Committee of the department, where appropriate, as to current pharmacy\npractice and drug marketing principles. (b) The department shall notify the\nmanufacturer(s) in writing of its intent to exclude a specific drug's\npackaging, dosage form or form of administration giving the reasons for the\nintended exclusion, together with the facts upon which the initial\ndetermination is based. (c) The\nmanufacturer(s) shall then have 15 days following receipt of notice of initial\ndetermination to notify the department in writing of intent to appeal the\ninitial determination. (1)\n\nFailure on the\npart of the manufacturer(s) to so notify the department of its intent to appeal\nwithin the 15 days, allows for immediate final determination to be made by the\ncommissioner. (2)\n\nIf the\nmanufacturer notifies the department of an intent to appeal, the manufacturer\nshall submit to the department, within 45 days of receiving the initial\ndetermination, all the information and documentation which forms the basis of\nthe manufacturer's appeal. (d) (1)\n\nThe\ndepartment, within 15 days of receiving the manufacturer's basis for appeal, shall provide to the manufacturer any additional facts concerning the intent to\nexclude a drug product to support the initial determination. (2)\n\nWithin 10 days of receiving such\nadditional facts, the manufacturer may submit to the department additional\nfacts relevant to the drug package, or form of dosage or\nadministration. (3)\n\nBased upon all\nof the facts and information gathered and submitted, the commissioner shall\nmake a final determination as to whether to designate a package, dosage form or\nform of administration, and exclude drug from program benefits\ncoverage. (4)\n\nAs final\ndeterminations of excluded drugs relating to package, dosage form or form of\nadministration are made by the commissioner pursuant to this subdivision, written notice of such determinations shall be made to the EPIC contractor by\nthe EPIC executive director and to the drug manufacturer of such drug\nproduct. Notes\nN.Y. Comp. Codes R. & Regs. Tit. 9\nยง\n9960.3\n\nState regulations are updated quarterly; we currently have two versions available. Below is a\ncomparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare. No prior version found.",
  "url_type": "regulation",
  "source_index": 8632
}